Developer docs
API playgroundTry for free, no card

Search company profiles

Veracyte

Full company profile

uuid0000d2p

Namestring
Veracyte
Legal namestring
Veracyte, Inc.
Websiteurl
veracyte.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Veracyte is a genomic diagnostics company that develops and commercializes molecular tests used by urologists, oncologists, and pathologists to inform cancer diagnosis, prognosis, and treatment decisions. Its core menu spans the Decipher Prostate and Decipher Bladder genomic classifiers for urologic cancers, the Prosigna breast cancer test, and the TrueMRD minimal residual disease franchise acquired via C2i Genomics. The underlying technology is built on proprietary whole-transcriptome and whole-genome profiling platforms, supported by the GRID (Genomic Resource for Intelligent Discovery) research database and the Veracyte Data Platform, which together form a data flywheel for biomarker and AI model development.\n\nThe company makes money primarily by selling proprietary laboratory-developed tests to physicians, with reimbursement secured from Medicare and commercial payers via established coverage policies; Prosigna is additionally being distributed as a kit to broaden the channel. Commercial operations are anchored in the United States, with a specialty sales force targeting high-decision-making urologists and academic centers, and the business was recently rationalized through the bankruptcy of the French Veracyte SAS subsidiary to focus on higher-return core markets. Revenue is generated per test ordered, with growth driven by menu expansion (metastatic prostate, bladder, MRD) and deepening utilization within existing accounts.\n\nThe platform's scale and sample-processing capacity, combined with extensive gene-level measurement across large annotated cohorts, position Veracyte as a data-rich diagnostics franchise rather than a single-product vendor. Ongoing investments in GRID and the Veracyte Data Platform support both internal test development and potential future AI/biomarker partnerships.

Short descriptiontext

Veracyte is a genomic diagnostics company that develops molecular tests — including Decipher Prostate, Decipher Bladder, Prosigna, and TrueMRD — used by urologists and oncologists to guide cancer diagnosis, prognosis, and treatment decisions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular cancer diagnostics, genomic testing services, laboratory developed tests, oncology biomarker testing, minimal residual disease monitoring
Industry4 codes
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cancer Molecular Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Genomic Diagnostic Testing Services
TypeOne Time License
Description

Veracyte generates revenue primarily through providing molecular diagnostic testing services to healthcare providers and patients. Tests are billed per test performed, with reimbursement from Medicare (CMS), commercial insurance plans, and patient self-pay. The company operates its tests as laboratory-developed tests (LDTs) under CLIA certification in its own labs. Revenue is recognized when test results are delivered.

finance.yahoo.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Afirma
Description

Genomic Sequencing Classifier for thyroid nodule testing

veracyte.com
+3 more records
Core offering1 text field

Veracyte develops and commercializes molecular diagnostic laboratory-developed tests (LDTs) for cancer, performed in its own CLIA-certified laboratories. Core offerings include the Afirma Genomic Sequencing Classifier for thyroid nodules, Decipher Prostate and Decipher Bladder genomic classifiers for urologic cancers, the Prosigna Breast Risk of Recurrence test, and the TrueMRD whole-genome minimal residual disease platform. Tests are reimbursed primarily through Medicare and commercial insurance, with revenue recognized upon delivery of test results.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 93.6-93.7% 5-year recurrence-free survival for breast cancer patients with low Prosigna scores treated with hormone therapy alone vs. 94.8-94.9% with chemotherapy (OPTIMA trial, n=4,400+)
+5 more records
Product overview1 text field

Veracyte offers a portfolio of genomic molecular diagnostic tests for cancer care spanning thyroid, prostate, bladder, breast, and lung cancers. The core offerings include five main laboratory-developed tests (LDTs): Afirma GSC for thyroid nodule diagnosis, Decipher Prostate and Decipher Bladder for urologic cancers, Prosigna Breast for breast cancer recurrence risk, and TrueMRD for minimal residual disease monitoring. These tests are unified by the Veracyte Diagnostics Platform, which performs whole-transcriptome analysis on every sample to generate an expanding database of genomic insights, and supported by the TrueMRD whole-genome MRD platform. The company also provides research-use-only databases (Decipher GRID and Afirma GRID) for collaborator access. Tests are primarily available in the United States through CLIA-certified laboratories, with Prosigna also available internationally as a CE-IVD product.

Product and service5 records
1Afirma Genomic Sequencing Classifier (GSC)
CategoryThyroid Cancer Molecular Diagnostics
Description

A whole-transcriptome genomic test performed on thyroid FNA samples to classify Bethesda III/IV nodules as Benign or Suspicious, helping endocrinologists and endocrine surgeons rule out cancer and avoid unnecessary thyroid surgery. Validated with 91% sensitivity and 96% negative predictive value.

2Decipher Prostate Genomic Classifier
CategoryProstate Cancer Molecular Diagnostics
Description

A 22-gene expression test measuring tumor aggressiveness in prostate cancer tissue to guide treatment decisions across localized, N1, and metastatic disease stages. The only gene expression test included in NCCN Guidelines for prostate cancer.

3Decipher Bladder Genomic Classifier
CategoryBladder Cancer Molecular Diagnostics
Description

A 219-gene molecular subtyping test that classifies bladder tumors by subtype (luminal versus non-luminal) to identify patients more likely to progress, be upstaged, or benefit from neoadjuvant chemo-immunotherapy.

4Prosigna Breast Risk of Recurrence Test
CategoryBreast Cancer Molecular Diagnostics
Description

A PAM50-based genomic test for early-stage hormone-receptor positive breast cancer that provides a Risk of Recurrence (ROR) score, 10-year distant recurrence probability, and chemotherapy benefit prediction. The only breast cancer test with Phase III Level 1A evidence for chemotherapy benefit prediction in patients with up to nine positive nodes.

5TrueMRD Monitoring Test for MIBC
CategoryMinimal Residual Disease Monitoring
Description

A tumor-informed whole-genome sequencing ctDNA test for minimal residual disease detection and recurrence monitoring in muscle-invasive bladder cancer patients post-cystectomy, detecting recurrence a median of 131 days earlier than standard imaging.

Scale indicator19 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Thyroid Cytopathology Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Thyroid Cytopathology Partners is a specialized cytopathology practice that provides primary thyroid cytopathology diagnosis with automatic reflex to Afirma GSC testing when indeterminate results are obtained. This partnership enables integrated cytology-plus-molecular testing workflow for thyroid nodule evaluation, allowing providers to order both services through a single process.

veracyte.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Natera develops and commercializes molecular diagnostic tests including Signatera (tumor-informed MRD) and Prospera (transplant rejection). Directly comparable to Veracyte in oncology MRD testing and CLIA-based laboratory services with strong salesforces targeting the same urology/oncology specialties.

TypeDirect peer
Description

Guardant Health offers liquid biopsy and genomic profiling tests (Guardant360, Guardant Reveal/MRD) for oncology. Competes head-to-head with Veracyte in cancer genomic profiling and MRD with similar business model (LDT services reimbursed by Medicare/commercial payers).

TypeDirect peer
Description

Exact Sciences is a leading cancer diagnostics company with Cologuard (CRC screening) and the Oncodetect MRD test. Comparable as a publicly-traded molecular diagnostics company with LDT/IVD offerings sold through Medicare/commercial reimbursement, leveraging whole-transcriptome/methylation approaches for cancer.

TypeDirect peer
Description

Myriad Genetics offers molecular diagnostic tests including Prolaris (prostate), myChoice HRD, and BRACAnalysis. Direct competitor in genomic cancer testing with similar payor model; notably Kevin Haas (Veracyte's new CDTO) joined from Myriad where he was CTO.

TypeDirect peer
Description

NeoGenomics provides oncology-focused clinical laboratory services including molecular testing, cytogenetics, and pathology. Competes with Veracyte in urologic and breast cancer molecular diagnostics, serving similar community oncology and hospital customers with CLIA-certified labs.

TypeDirect peer
Description

Foundation Medicine develops comprehensive genomic profiling tests (FoundationOne CDx, FoundationOne Liquid CDx) for solid tumors. Directly competes with Veracyte in oncology tumor profiling with similar LDT/Medicare-coverage model; operates as a subsidiary of Roche for global scale.

TypeEmerging player
Description

Caris offers MI Profile (multi-platform molecular profiling) and Caris Assure MRD. Competes with Veracyte's Decipher in prostate and oncology molecular profiling but with broader multi-cancer focus. Private company with growing commercial presence.

8Tempus AI
TypeEmerging player
Description

Tempus provides AI-driven precision medicine including genomics profiling, MRD (Tempus xT/xR), and data analytics for oncology. Comparable platform/data-aggregation approach and oncology-focused molecular diagnostics; emerging public competitor with broad multimodal ambitions.

TypeEmerging player
Description

Personalis offers NeXT Personal (tumor-informed MRD) and ImmunoID NeXT for cancer immunotherapy. Comparable in MRD technology and oncology focus with whole-genome/whole-transcriptome sequencing capabilities overlapping Veracyte's TrueMRD platform.

TypeBroad incumbent
Description

Bio-Rad is a major life science and clinical diagnostics company with Droplet Digital PCR and other molecular diagnostic technologies. Provides underlying instrumentation and reagents for molecular diagnostics, including platforms used in CLIA-validated cancer tests like those Veracyte operates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Veracyte

Cancer Molecular Diagnosticsveracyte.com

Veracyte is a genomic diagnostics company that develops molecular tests — including Decipher Prostate, Decipher Bladder, Prosigna, and TrueMRD — used by urologists and oncologists to guide cancer diagnosis, prognosis, and treatment decisions.

What Veracyte does

Veracyte is a genomic diagnostics company that develops and commercializes molecular tests used by urologists, oncologists, and pathologists to inform cancer diagnosis, prognosis, and treatment decisions. Its core menu spans the Decipher Prostate and Decipher Bladder genomic classifiers for urologic cancers, the Prosigna breast cancer test, and the TrueMRD minimal residual disease franchise acquired via C2i Genomics. The underlying technology is built on proprietary whole-transcriptome and whole-genome profiling platforms, supported by the GRID (Genomic Resource for Intelligent Discovery) research database and the Veracyte Data Platform, which together form a data flywheel for biomarker and AI model development.\n\nThe company makes money primarily by selling proprietary laboratory-developed tests to physicians, with reimbursement secured from Medicare and commercial payers via established coverage policies; Prosigna is additionally being distributed as a kit to broaden the channel. Commercial operations are anchored in the United States, with a specialty sales force targeting high-decision-making urologists and academic centers, and the business was recently rationalized through the bankruptcy of the French Veracyte SAS subsidiary to focus on higher-return core markets. Revenue is generated per test ordered, with growth driven by menu expansion (metastatic prostate, bladder, MRD) and deepening utilization within existing accounts.\n\nThe platform's scale and sample-processing capacity, combined with extensive gene-level measurement across large annotated cohorts, position Veracyte as a data-rich diagnostics franchise rather than a single-product vendor. Ongoing investments in GRID and the Veracyte Data Platform support both internal test development and potential future AI/biomarker partnerships.

Veracyte firmographics

Firmographics
Name
Veracyte
Legal name
Veracyte, Inc.
Website
https://veracyte.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Veracyte is a genomic diagnostics company that develops molecular tests — including Decipher Prostate, Decipher Bladder, Prosigna, and TrueMRD — used by urologists and oncologists to guide cancer diagnosis, prognosis, and treatment decisions.
Ownership category
akta.pro rank

Veracyte industry classification

Industry
Product category
Cancer Molecular Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Molecular cancer diagnostics
  • Genomic testing services
  • Laboratory developed tests
  • Oncology biomarker testing
  • Minimal residual disease monitoring

Where Veracyte is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Veracyte business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Genomic Diagnostic Testing Services: Veracyte generates revenue primarily through providing molecular diagnostic testing services to healthcare providers and patients. Tests are billed per test performed, with reimbursement from Medicare (CMS), commercial insurance plans, and patient self-pay. The company operates its tests as laboratory-developed tests (LDTs) under CLIA certification in its own labs. Revenue is recognized when test results are delivered.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Veracyte product offering

Product offering

Core offering

Veracyte develops and commercializes molecular diagnostic laboratory-developed tests (LDTs) for cancer, performed in its own CLIA-certified laboratories. Core offerings include the Afirma Genomic Sequencing Classifier for thyroid nodules, Decipher Prostate and Decipher Bladder genomic classifiers for urologic cancers, the Prosigna Breast Risk of Recurrence test, and the TrueMRD whole-genome minimal residual disease platform. Tests are reimbursed primarily through Medicare and commercial insurance, with revenue recognized upon delivery of test results.

Product overview

Veracyte offers a portfolio of genomic molecular diagnostic tests for cancer care spanning thyroid, prostate, bladder, breast, and lung cancers. The core offerings include five main laboratory-developed tests (LDTs): Afirma GSC for thyroid nodule diagnosis, Decipher Prostate and Decipher Bladder for urologic cancers, Prosigna Breast for breast cancer recurrence risk, and TrueMRD for minimal residual disease monitoring. These tests are unified by the Veracyte Diagnostics Platform, which performs whole-transcriptome analysis on every sample to generate an expanding database of genomic insights, and supported by the TrueMRD whole-genome MRD platform. The company also provides research-use-only databases (Decipher GRID and Afirma GRID) for collaborator access. Tests are primarily available in the United States through CLIA-certified laboratories, with Prosigna also available internationally as a CE-IVD product.

Differentiator

Problem solved

Functional benefit

Brands

  • Afirma: Genomic Sequencing Classifier for thyroid nodule testing
  • Decipher
  • Prosigna
  • TrueMRD

Products and services

  • Afirma Genomic Sequencing Classifier (GSC) A whole-transcriptome genomic test performed on thyroid FNA samples to classify Bethesda III/IV nodules as Benign or Suspicious, helping endocrinologists and endocrine surgeons rule out cancer and avoid unnecessary thyroid surgery. Validated with 91% sensitivity and 96% negative predictive value.
  • Decipher Prostate Genomic Classifier A 22-gene expression test measuring tumor aggressiveness in prostate cancer tissue to guide treatment decisions across localized, N1, and metastatic disease stages. The only gene expression test included in NCCN Guidelines for prostate cancer.
  • Decipher Bladder Genomic Classifier A 219-gene molecular subtyping test that classifies bladder tumors by subtype (luminal versus non-luminal) to identify patients more likely to progress, be upstaged, or benefit from neoadjuvant chemo-immunotherapy.
  • Prosigna Breast Risk of Recurrence Test A PAM50-based genomic test for early-stage hormone-receptor positive breast cancer that provides a Risk of Recurrence (ROR) score, 10-year distant recurrence probability, and chemotherapy benefit prediction. The only breast cancer test with Phase III Level 1A evidence for chemotherapy benefit prediction in patients with up to nine positive nodes.
  • TrueMRD Monitoring Test for MIBC A tumor-informed whole-genome sequencing ctDNA test for minimal residual disease detection and recurrence monitoring in muscle-invasive bladder cancer patients post-cystectomy, detecting recurrence a median of 131 days earlier than standard imaging.

Quantifiable outcome

  • 93.6-93.7% 5-year recurrence-free survival for breast cancer patients with low Prosigna scores treated with hormone therapy alone vs. 94.8-94.9% with chemotherapy (OPTIMA trial, n=4,400+)
  • +5 more outcomes

Companies that use Veracyte

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles4 records

Veracyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Veracyte partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Thyroid Cytopathology PartnerscoreStrategic or Co-development PartnerThyroid Cytopathology Partners is a specialized cytopathology practice that provides primary thyroid cytopathology diagnosis with automatic reflex to Afirma GSC testing when indeterminate results are obtained. This partnership enables integrated cytology-plus-molecular testing workflow for thyroid nodule evaluation, allowing providers to order both services through a single process.

Scale indicators19 records

Recent moves7 records

Expansion highlights5 records

Veracyte competitors and assessment

Company assessment

Direct peers

  • Natera: Natera develops and commercializes molecular diagnostic tests including Signatera (tumor-informed MRD) and Prospera (transplant rejection). Directly comparable to Veracyte in oncology MRD testing and CLIA-based laboratory services with strong salesforces targeting the same urology/oncology specialties.
  • Guardant Health: Guardant Health offers liquid biopsy and genomic profiling tests (Guardant360, Guardant Reveal/MRD) for oncology. Competes head-to-head with Veracyte in cancer genomic profiling and MRD with similar business model (LDT services reimbursed by Medicare/commercial payers).
  • Exact Sciences: Exact Sciences is a leading cancer diagnostics company with Cologuard (CRC screening) and the Oncodetect MRD test. Comparable as a publicly-traded molecular diagnostics company with LDT/IVD offerings sold through Medicare/commercial reimbursement, leveraging whole-transcriptome/methylation approaches for cancer.
  • Myriad Genetics: Myriad Genetics offers molecular diagnostic tests including Prolaris (prostate), myChoice HRD, and BRACAnalysis. Direct competitor in genomic cancer testing with similar payor model; notably Kevin Haas (Veracyte's new CDTO) joined from Myriad where he was CTO.
  • NeoGenomics: NeoGenomics provides oncology-focused clinical laboratory services including molecular testing, cytogenetics, and pathology. Competes with Veracyte in urologic and breast cancer molecular diagnostics, serving similar community oncology and hospital customers with CLIA-certified labs.
  • Foundation Medicine (Roche): Foundation Medicine develops comprehensive genomic profiling tests (FoundationOne CDx, FoundationOne Liquid CDx) for solid tumors. Directly competes with Veracyte in oncology tumor profiling with similar LDT/Medicare-coverage model; operates as a subsidiary of Roche for global scale.

Emerging players

  • Caris Life Sciences: Caris offers MI Profile (multi-platform molecular profiling) and Caris Assure MRD. Competes with Veracyte's Decipher in prostate and oncology molecular profiling but with broader multi-cancer focus. Private company with growing commercial presence.
  • Tempus AI: Tempus provides AI-driven precision medicine including genomics profiling, MRD (Tempus xT/xR), and data analytics for oncology. Comparable platform/data-aggregation approach and oncology-focused molecular diagnostics; emerging public competitor with broad multimodal ambitions.
  • Personalis: Personalis offers NeXT Personal (tumor-informed MRD) and ImmunoID NeXT for cancer immunotherapy. Comparable in MRD technology and oncology focus with whole-genome/whole-transcriptome sequencing capabilities overlapping Veracyte's TrueMRD platform.

Broad incumbents

  • Bio-Rad Laboratories: Bio-Rad is a major life science and clinical diagnostics company with Droplet Digital PCR and other molecular diagnostic technologies. Provides underlying instrumentation and reagents for molecular diagnostics, including platforms used in CLIA-validated cancer tests like those Veracyte operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Veracyte social profiles

Digital presence

Veracyte compliance and trust

Trust signal

Compliance7 records

Veracyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Veracyte leadership team

Management profile

Number of profiles

Profiles9 records

Veracyte subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Veracyte funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Veracyte M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Veracyte

What does Veracyte do?

Veracyte develops and commercializes molecular diagnostic laboratory-developed tests (LDTs) for cancer, performed in its own CLIA-certified laboratories. Core offerings include the Afirma Genomic Sequencing Classifier for thyroid nodules, Decipher Prostate and Decipher Bladder genomic classifiers for urologic cancers, the Prosigna Breast Risk of Recurrence test, and the TrueMRD whole-genome minimal residual disease platform. Tests are reimbursed primarily through Medicare and commercial insurance, with revenue recognized upon delivery of test results.

Is Veracyte a public or private company?

Veracyte is a public company. It is classified as public and is currently operating.

When was Veracyte founded?

Veracyte was founded in 2008. It employs 501 to 1,000 people.

Where is Veracyte based?

Veracyte is headquartered in South San Francisco, United States, in the North America region.

How does Veracyte make money?

One revenue line is on record: genomic Diagnostic Testing Services.

Who are Veracyte's main competitors?

Direct peers on record are Natera, Guardant Health, Exact Sciences, Myriad Genetics, NeoGenomics and Foundation Medicine (Roche). Emerging players are Caris Life Sciences, Tempus AI and Personalis. Bio-Rad Laboratories is listed as a broad incumbent.

Does Veracyte have an API?

No public API is recorded for Veracyte.

What industry is Veracyte in?

Veracyte's product category is Cancer Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireVeracyte (VCYT) Securities Investigation Notice - Levi & KorsinskyNeedham cut its Veracyte price target by $23 per share after the company's November 4, 2026 outlook reset on its Decipher Prostate test. Levi & Korsinsky is investigating potential securities law violations on behalf of VCYT shareholders who lost money. The investigation concerns whether Veracyte's statements about the test's growth outlook were accurate and complete.Seeking AlphaVeracyte: Solid Profits, Slowing Tests, And A Stock In LimboVeracyte reported Q3 revenue of $151.8 million, up 15% year over year, but Decipher test volumes fell short by about 1,000. Management cut its 2027 test-volume growth outlook to 12,000–15,000, a 40% slowdown. The stock trades at 2.87x forward sales, and the company holds a Hold rating.TradingViewStephens & Co. maintains Veracyte at Overweight, lowers price target to $40 from $55Stephens & Co. maintained Veracyte at Overweight and lowered its price target to $40 from $55, a 27.3% decrease. The target implies a 66.3% upside from the Nov 10 close of $24.06. Recent analyst price targets on Veracyte range from $30 to $46.Simply Wall StVeracyte (VCYT) Shares Dropped, So What Is Driving Attention Now?Veracyte reported Q3 results, trimmed full-year revenue guidance, and authorized a $100 million buyback, causing its shares to fall 7.2% in one session and 52.2% over the past week. Analysts see a fair value of $59.73 versus a last close of $24.06, citing pipeline momentum but also execution and reimbursement risks.Seeking AlphaVeracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference TranscriptVeracyte's CEO Marc Stapley and CFO Rebecca Chambers presented at the 2026 UBS Global Healthcare Conference, addressing Q3 updates and product outlook. The stock fell after the company revised its Decipher volume growth outlook, which lowered revenue growth and EBITDA margins. The presentation also covered product positioning for 2027 and beyond.Investing.comVeracyte at UBS Global Healthcare Conference: growth plan beyond DecipherVeracyte defended its outlook at the UBS Global Healthcare Conference, citing Decipher volume normalization after guideline-driven growth. The company guided to double-digit volume growth but mid-single-digit revenue growth for 2027, with Afirma as a core engine and Prosigna and bladder tests as future opportunities. It also initiated a $100 million buyback.American Banking and Market News51,392 Veracyte, Inc. $VCYT Shares Purchased by Candriam S.C.A.Candriam S.C.A. increased its Veracyte stake by 38.1% in Q3, buying 51,392 shares. Veracyte reported Q3 EPS of $0.51, beating estimates, with revenue up 15.1% year-over-year. Analysts rate the stock a Hold with a consensus price target of $48.40.American Banking and Market NewsVeracyte (NASDAQ:VCYT) Cut to “Hold” at Wall Street ZenWall Street Zen cut Veracyte from a buy to a hold rating. The stock opened at $25.92, and Veracyte reported Q3 EPS of $0.51, beating estimates, with revenue of $151.75 million, up 15.1% year-over-year. Analysts have an average price target of $48.40.FinancialContent Business PageVCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS LawSchall, Brown & Schwartz LLP is investigating Veracyte, Inc. for securities law violations, including false or misleading statements. The investigation follows Veracyte's lowered 2026 revenue guidance, which caused its stock to drop nearly 50%. The firm invites affected shareholders to participate.ChartmillVeracyte (NASDAQ:VCYT): An Undervalued Value Stock With Quality FundamentalsVeracyte is presented as an undervalued value stock with a 7/10 rating from ChartMill, citing a P/E of 14.38 versus an industry average of 39.50. The company reports a 20.37% profit margin, a debt-free balance sheet, and forecast EPS growth of 20.99% annually. Risks include no dividend, share dilution, and ROIC below WACC.